Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Share-based Compensation (2016 - 2025)

Cardiff Oncology's Share-based Compensation history spans 15 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 4.73% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $5.7 million, up 19.6%, while the annual FY2025 figure was $5.7 million, 19.6% up from the prior year.
  • Share-based Compensation for Q4 2025 was $1.3 million at Cardiff Oncology, down from $1.4 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $1.7 million in Q2 2025 and bottomed at $268000.0 in Q1 2021.
  • The 5-year median for Share-based Compensation is $1.1 million (2023), against an average of $1.1 million.
  • The largest annual shift saw Share-based Compensation surged 329.85% in 2022 before it dropped 25.43% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $990000.0 in 2021, then rose by 2.22% to $1.0 million in 2022, then dropped by 10.18% to $909000.0 in 2023, then soared by 32.45% to $1.2 million in 2024, then grew by 4.73% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Share-based Compensation are $1.3 million (Q4 2025), $1.4 million (Q3 2025), and $1.7 million (Q2 2025).